A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.
The 2024-2025 mRNA COVID-19 vaccine provided moderate protection against severe outcomes, including hospitalizations and ED visits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results